Pfizer Inc. CEO Ian Read suggested the company isn't going to back off its customary January price increases, even with ongoing pressure coming from the Trump Administration. Read was pressed by analysts during the company's third quarter earnings call Oct. 30 about expectations for the annual drug price increases that are generally taken at the beginning of the year.
"I expect our approach by the end of the year will be what I would characterize as business as normal,"...